Back to Research

Organization profile

Rheon Medical

Rheon Medical is a high-growth Swiss medtech company that developed the eyeWatch, the world’s first non-invasively adjustable glaucoma drainage system. An EPFL spin-off, the firm utilizes advanced micromechanical and magnetic control technology to allow ophthalmologists to precisely titrate intraocular pressure in an office-based procedure, significantly improving surgical safety and long-term vision preservation.

Préverenges, SwitzerlandFounded 2010

Overview

1. Executive Summary (Confidence: High)

Rheon Medical represents a "Revolution in Glaucoma Treatment," addressing the single greatest clinical challenge in ophthalmic surgery: the lack of post-operative flow control. Founded as a spin-off from the Swiss Federal Institute of Technology Lausanne (EPFL), the company has commercialized the eyeWatch, a device that integrates Swiss watchmaking precision with advanced medical micromechanics. Since receiving the CE Mark in 2019 and FDA Breakthrough Device Designation in 2021, Rheon has successfully implanted the system in over 1,250 patients worldwide. Clinical data across one- and three-year periods demonstrate an exceptional ability to maintain target intraocular pressure () while reducing the need for medications by up to 60%. Positioned as the primary innovator in the refractory glaucoma market, Rheon is currently scaling its global distribution and pursuing full US regulatory approval.

Unlock the full profileGet the complete company dossier

This public view only shows an extract. Open the full profile to access the complete company intelligence record, including the full write-up and structured research details.

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.